Richard M. Stone, MD

Publications

• O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES.Acute myeloid leukemia.J Nat
  21393440
• Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A.Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.J Clin Oncol. 2011 Mar 1;29(7):789-96.
  21220608
• Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P.My
  21233243
• Stone RM.New agents in post-remission therapy.Best Pract Res Clin Haematol. 2010 Dec;23(4):475-9.
  21130410
• Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA.Arsenic trioxide improves event-free and over-all survival for adults with acute promyelocytic leukemi
  20705755
• Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD
  20656931
• Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ.Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyros
  20733134
• Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, Adamia S, Kung AL, Gray NS, Griffin JD.Discovery and characterization of novel mutant FLT3 kinase inhibitors.Mol Cancer Ther. 2010 Sep;9(9):2
  20807780
• Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A.CNS relapse in acute promyeloctyic leukemia.J Clin Oncol. 2010 Aug 20;28(24):e409-11.
  20530270
• Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA, .High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia
  20688393
• Abel GA, Van Bennekom CM, Stone RM, Anderson TE, Kaufman DW.Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients.Leuk Res. 2010 Jul;34(7):939-41.
  20138359
• Motyckova G, Stone RM.The role of molecular tests in acute myelogenous leukemia treatment decisions.Curr Hematol Malig Rep. 2010 Apr;5(2):109-17. Review.
  20425404
• Steensma DP, Stone RM.Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406. Review.
  20359633
• Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D.Generation of Tumor-specific T Lymphocytes Usin
  20145548
• Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Wei
  20018760
• Stone RM.Prognostic factors in AML in relation to (ab)normal karyotype.Best Pract Res Clin Haematol. 2009 Dec;22(4):523-8. Review.
  19959103
• Rhodes J, Amsterdam A, Sanda T, Moreau LA, McKenna K, Heinrichs S, Ganem NJ, Ho KW, Neuberg DS, Johnston A, Ahn Y, Kutok JL, Hromas R, Wray J, Lee C, Murphy C, Radtke I, Downing JR, Fleming MD, MacConaill LE, Amatruda JF, Gutierrez A, Galinsky I, Stone RM
  19704007
• Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, Ross L, Galinsky I, Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M, Hahn WC, Carr SA, Golub TR, Kung AL, Stegmaier K.Proteomic and genetic approaches identify Syk as an AML
  19800574
• Stone RM, DeAngelo DJ.Screens, iron, and leukemia.Blood. 2009 Oct 1;114(14):2857-8.
  19797531
• Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, Maslyar DJ, Hege KM.Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell
  19556425
• Apperley JF,Cortes JE,Kim DW,Roy L,Roboz GJ,Rosti G,Bullorsky EO,Abruzzese E,Hochhaus A,Heim D,de Souza CA,Larson RA,Lipton JH,Khoury HJ,Kim HJ,Sillaber C,Hughes TP,Erben P,Van Tornout J,Stone RM.Dasatinib in the Treatment of Chronic Myeloid Leukemia in A
  19487385
• Abdel-Wahab O,Mullally A,Hedvat C,Garcia-Manero G,Patel J,Wadleigh M,Malinge S,Yao J,Kilpivaara O,Bhat R,Huberman K,Thomas S,Dolgalev I,Heguy A,Paietta E,Le Beau MM,Beran M,Tallman MS,Ebert BL,Kantarjian HM,Stone RM,Gilliland DG,Crispino JD,Levine RL.Gene
  19420352
• Stone RM.How I treat patients with myelodysplastic syndromes.Blood. 2009 Jun 18;113(25):6296-303. Review.
  19383969
• Weisberg E,Barrett R,Liu Q,Stone R,Gray N,Griffin JD.FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.Drug Resist Updat. 2009 Jun;12(3):81-9. Review.
  19467916
• Corsello SM,Roti G,Ross KN,Chow KT,Galinsky I,Deangelo DJ,Stone RM,Kung AL,Golub TR,Stegmaier K.Identification of AML1-ETO modulators by chemical genomics.Blood. 2009 Jun 11;113(24):6193-205.
  19377049
• Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete re
  19509382
• Kilpivaara O,Mukherjee S,Schram AM,Wadleigh M,Mullally A,Ebert BL,Bass A,Marubayashi S,Heguy A,Garcia-Manero G,Kantarjian H,Offit K,Stone RM,Gilliland DG,Klein RJ,Levine RL.A germline JAK2 SNP is associated with predisposition to the development of JAK2(V
  19287384
• Wadleigh M,Stone RM.The role of myeloid growth factors in acute leukemia.J Natl Compr Canc Netw. 2009 Jan;7(1):84-91. Review.
  19176208
• O'Donnell MR,Appelbaum FR,Coutre SE,Damon LE,Erba HP,Foran J,Lancet J,Maness LJ,Marcucci G,Maslak PG,Millenson M,Moore JO,Ravandi F,Schuening F,Shami P,Smith BD,Stone RM,Tallman MS,Wang E,White FL.Acute myeloid leukemia.J Natl Compr Canc Netw. 2008 No
  19176196
• Stone RM.Are new agents really making a difference in MDS?.Best Pract Res Clin Haematol. 2008 Dec;21(4):639-46. Review.
  19041603
• Grinblatt DL,Yu D,Hars V,Vardiman JW,Powell BL,Nattam S,Silverman LR,de Castro C 3rd,Stone RM,Bloomfield CD,Larson RA.Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia
  19025972
• Fonseca C,Soiffer R,Ho V,Vanneman M,Jinushi M,Ritz J,Neuberg D,Stone R,DeAngelo D,Dranoff G.Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.Blood. 2009 Feb 19;113(8):1681-8.
  19008459
• Greenberg PL,Attar E,Battiwalla M,Bennett JM,Bloomfield CD,DeCastro CM,Deeg HJ,Erba HP,Foran JM,Garcia-Manero G,Gore SD,Head D,Maness LJ,Millenson M,Nimer SD,O'Donnell MR,Saba HI,Shami PJ,Spiers K,Stone RM,Tallman MS,Westervelt P.Myelodysplastic syndr
  18926100
• Weisberg E,Roesel J,Bold G,Furet P,Jiang J,Cools J,Wright RD,Nelson E,Barrett R,Ray A,Moreno D,Hall-Meyers E,Stone R,Galinsky I,Fox E,Gilliland G,Daley JF,Lazo-Kallanian S,Kung AL,Griffin JD.Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST
  18820131
• Stone RM,DeAngelo DJ,Janosova A,Galinsky I,Canning C,Ritz J,Soiffer RJ.Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.Am J Hematol. 2008 Oct;83(10):771-7.
  18756547
• Stone RM,Donohue KA,Stock W,Hars V,Linker CA,Shea T,Deangelo DJ,Marcucci G,Bloomfield CD,Larson RA.A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.Cancer
  18670778
• Kesari S,Drappatz J,Akar S,Vergilio JA,Wen PY,Soiffer RJ,Stone RM,Deangelo DJ.Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass.J Clin Oncol. 2008 Jul 1;26(19):3279-81.
  18591563
• Baer MR,George SL,Caligiuri MA,Sanford BL,Bothun SM,Mrozek K,Kolitz JE,Powell BL,Moore JO,Stone RM,Anastasi J,Bloomfield CD,Larson RA.Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leuke
  18591543
• Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, Adamia S, Stone R, Galinsky I, Kung AL, Griffin JD.Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.Mol Cancer Ther. 2008 May;7(5):1121-9.
  18445657
• Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA.Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia - Cance
  18452072
• Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC.Phase I and pharmacokinetic study of bortezomib in combination
  18316568
• Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J, Tanguturi S, Ladd-Acosta C, Stone R, Golub TR, Raza A.An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.PLoS Med. 2008 Feb;5(2):e35.
  18271621
• Loriaux MM, Levine RL, Tyner JW, Frohling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC, Deininger MW, Gilliland DG, Druker BJ.High-throughput sequence analysis of the
  18252861
• Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y, Stewart S, Stone RM, Tallman MS, McCarthy PL Jr, Hahn T.The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults:
  18215777
• Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, Stone R, Galinsky I, Fox E, Kung AL, Griffin JD.Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on B
  18184863
• Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, Wright JJ, Harousseau JL, Lowenberg B, Stone RM, De Porre P, Wang Y, Karp JE.A 2-gene classifier for predicting response to the farnesyltransferase inhibit
  18160667
• Kawano T, Ito M, Raina D, Wu Z, Rosenblatt J, Avigan D, Stone R, Kufe D.MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.Cancer Res. 2007 Dec 15;67(24):11576-84.
  18089786
• Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Dohner H, Dohner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG.Identification of dri
  18068628
• Deangelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA.Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphom
  17344466
• Armand P, Kim HT, Deangelo DJ, Ho VT, Cutler CS, Stone RM, Ritz J, Alyea EP, Antin JH, Soiffer RJ.Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation.Biol Blood Marrow Transplant. 2007 Jun;13(6):65
  17531775
• Stone RM.Novel therapeutic agents in acute myeloid leukemia.Exp Hematol. 2007 Apr;35(4 Suppl 1):163-6. Review.
  17379102
• Stone RM.Targeted agents in AML: much more to do.Best Pract Res Clin Haematol. 2007 Mar;20(1):39-48. Review.
  17336253
• Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G,
  17151364
• Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP.Dasatinib induces notable hematologic and cytog
  17138817
• Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, Larson RA, Lee SJ, Murphy SB, O'Brien S, Radich J, Scher NS, Smith FO, Stone RM, Tallman MS.End points to establish the efficacy of new agents in the treatment of acute leukemi
  17095617
• Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, Ritz J, Antin JH, Soiffer RJ.Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
  17067911
• DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC.Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patien
  16902153
• Larson RA, Stone RM, Mayer RJ, Schiffer CA.Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3556s-63s. Review.
  16740785
• Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CD.Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.Int J Oncol. 2006 May;28(5):1099-103.
  16596225
• Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG.Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412.Blood. 2005 Jul 15;106(2):721-4.
  15790786
• Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC.Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed a
  15730852
• Alyea EP, Kim HT, Ho VT, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S, Ritz J, Stone RM, Antin JH, Soiffer RJ.Comparative outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients greater than fifty y
  15459007
• Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD.Acute myeloid leukemia patients with an activating mutation in FLT3 respond to a small molecule FLT
  15345597
• Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD.Outcome of induction and postremission therapy in yo
  15534356
• Levine RL, Wadleigh M, Sternberg DW, Wlodarska I, Galinsky I, Stone RM, DeAngelo DJ, Gilliland DG, Cools J.KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).Leukemia. 2005 Jan;19
  15496975
• Gong J, Koido S, Kato Y, Tanaka Y, Chen D, Jonas A, Galinsky I, DeAngelo D, Avigan D, Kufe D, Stone R.Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts.Leuk Res. 2004 Dec;28(12):130
  15475072
• Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Galinsky I, Huntly B, Cohen PS, Meyer T, Fabbro D, Roesel J, Banerji L, Griffin JD, Xiao S, Fletcher JA, Stone RM, Gilliland DG.PKC412 inh
  15448205
• Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM.After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.Blood. 2005 Jan 1;105(1):22-30.
  15358622
• Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR.Identification and Characterization of a Novel Activating Mutation
  15178581
• DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic trans
  15297408
• Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ.Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome.Leukemia. 2004 Apr;18(4):809-16.
  14762444
• Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, Gilliland DG.PKC412
  12781364
• Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ.Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allog
  12738663
• Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Co
  12660384
• Stone RM.Induction and postremission therapy: new agents.Leukemia. 2003 Mar;17(3):496-8.
  12646937
• Wu CJ, Neuberg D, Chillemi A, McLaughlin S, Hochberg EP, Galinsky I, DeAngelo D, Soiffer RJ, Alyea EP, Capdeville R, Stone RM, Ritz J.Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.Leuk Lymphoma. 2002 Dec;43(12):2281-9.
  12613514
• Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ.Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogenei
  12463479
• Stone RM.Treatment of acute myeloid leukemia: state-of-the-art and future directions.Semin Hematol. 2002 Jul;39(3 Suppl 2):4-10.
  12214287
• Stone RM.New therapies in leukemia: renewed hope.J Hematother Stem Cell Res. 2002 Aug;11(4):583-7.
  12201947
• Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J.CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in pa
  11181681
• Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM.A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients
  10753831
• Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS.Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma
  10506609
• Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA.A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acut
  9716583
• Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, Stone R, Weissman SM, Hudson TJ, Fletcher JA.FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.Nat Genet. 1998 Jan;18(1):84-7.
  9425908
• Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J.CD6-depleted allogeneic bone marrow transplantation for acute leukemia i
  9108425
• Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA.Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and
  7760868
• Inhorn RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R, Stone RM.A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.Bloo
  7661940
• Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P, Freedman AS.Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.J Clin Oncol. 199
  7989927
• Stone RM, Bernstein SH, Demetri G, Facklam DP, Arthur K, Andersen J, Aster JC, Kufe D.Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes.Leuk Res. 1994 Oct;18(10):769-76.
  7934135
• Stone RM.Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress.Blood. 1994 Jun 15;83(12):3437-40.
  8204870
• Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW.Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes.Am J Clin Oncol. 1993 Apr;16(2):159-63.
  8452111
• Stone RM, Imamura K, Datta R, Sherman ML, Kufe DW.Inhibition of phorbol ester-induced monocytic differentiation and c-fms gene expression by dexamethasone: potential involvement of arachidonic acid metabolites.Blood. 1990 Sep 15;76(6):1225-32.
  2144778
• Stone RM, Sariban E, Pettit GR, Kufe DW.Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells.Blood. 1988 Jul;72(1):208-13.
  2455568
• Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ.Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients.Blood. 1988 Mar;71(3):690-6
  3422828